Drug Trial Radar · NCT01155466
A Placebo- and Active Controlled Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (P04938)
Last checked: Nov 20, 2026Latest source record: Nov 6, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
778
Actual
Start
Jul 14, 2010
Primary completion
Dec 20, 2012
Study completion Dec 20, 2012
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Jul 1, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 30 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
When a patient with Parkinson's disease (PD) is initially treated with L-dopa or dopamine agonists, the symptoms of PD improve or disappear. After several years of taking L dopa or dopamine agonists, patients notice that their PD medications wear off sooner than when they first started taking them. This "wearing off" is characterized by the return of symptoms (i.e., tremor, slowness, and rigidity) and may occur over the course of a few minutes to an hour. When a patient's PD symptoms have returned, the patient is said to be in the "off" state. When the patient takes another dose of medication, and his/her PD symptoms improve or resolve, the patient is said to be in the "on" state. Antagonism of adenosine Type 2a receptors (A2a) may provide relief of PD symptoms. This trial will test the hypothesis that A2a receptor antagonism can lead to improvement in the function of PD participants taking a stable dose of L-dopa, as measured by a reduction in "off" time.
Conditions
- Parkinson Disease
Interventions
Preladenant 2 mg tabletDrug
one 2 mg tablet orally twice daily
Preladenant 5 mg tabletDrug
one 5 mg tablet orally twice daily
Preladenant 10 mg tabletDrug
one 10 mg tablet orally twice daily
Placebo to Preladenant TabletDrug
one tablet orally twice daily
Rasagiline 1 mg capsuleDrug
one 1 mg capsule orally in AM
Placebo to Rasagiline capsuleDrug
one capsule orally in AM
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Mean "Off" TimeTime frame: Baseline and Week 12
- Numberof Participants With Systolic Blood Pressure >=180 mm HgTime frame: Up to Week 14
- Number of Participants With Diastolic Blood Pressure >=105 mm HgTime frame: Up to Week 14
- Number of Participants With Alanine Aminotransferase >=3 Times the Upper Limit of NormalTime frame: Up to Week 14
- Number of Participants With Aspartate Aminotransferase >=3 Times the Upper Limit of NormalTime frame: Up to Week 14
- Percentage of Participants With SuicidalityTime frame: Up to Week 12
- Change From Baseline at Week 12 in Epworth Sleepiness Scale (ESS)Time frame: Baseline and Week 12
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.